Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An H<sub>2</sub>O<sub>2</sub> and MPO programmable responsive MRI probe for early detection of drug-induced acute kidney injury via spatiotemporal monitoring of renal oxidative stress and inflammation.

Redox biology·2026
Same author

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts.

EJHaem·2026
Same author

Single-dose X-ray driven persistent activation of nanoprodrugs for radio-chemo-immunotherapy.

Journal of nanobiotechnology·2026
Same author

[Clinical study on bi-rooted primary canines].

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology·2026
Same author

Berberine Reduces Atrial Lipotoxicity and Endoplasmic Reticulum Stress to Alleviate Heart Failure With Preserved Ejection Fraction (HFpEF)-Associated Atrial Fibrillation via AMPK Signaling.

Phytotherapy research : PTR·2026
Same author

MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway.

Annals of hematology·2026

Related Experiment Video

Updated: Jun 11, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Peptide-based immunotherapy for multiple myeloma: current approaches.

Fu-Ling Zhou1, Shan Meng, Wang-Gang Zhang

  • 1Department of Clinical Hematology, The Affiliated No. 2 Hospital, Xi'an Jiaotong University, The West Five Road, No. 157, Xi'an 710004, PR China. zhoufuling@163.com

Vaccine
|July 13, 2010
PubMed
Summary

Peptide-based immunotherapy offers a promising strategy to selectively target and eliminate multiple myeloma (MM) cells by harnessing cytotoxic T-cell responses. Ongoing research focuses on optimizing peptide selection and vaccine formulations for enhanced efficacy in MM treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Multiple myeloma (MM) is a fatal B-cell malignancy with limited cure rates despite current therapies.
  • Immunotherapy presents a promising avenue for selective targeting and elimination of myeloma cells.
  • Peptide-based immunotherapy, leveraging cytotoxic T-cell responses, has garnered significant research interest.

Purpose of the Study:

  • To review previous immunotherapy trials for multiple myeloma.
  • To describe current strategies in peptide-based immunotherapy for MM.
  • To discuss future prospects of peptide immunotherapy in MM treatment.

Main Methods:

  • Review of existing literature on multiple myeloma immunotherapy trials.
  • Analysis of identified epitope peptides for targeted immune responses.
  • Evaluation of various approaches to enhance peptide immunogenicity.

Main Results:

  • Identification of specific epitope peptides for selective targeting of myeloma cells.
  • Development of diverse strategies to augment peptide-induced immune responses.
  • Accumulation of data from various immunotherapy trials in MM.

Conclusions:

  • Peptide-based immunotherapy is a viable and evolving strategy for multiple myeloma.
  • Optimization of epitope selection, vaccine formulation, and clinical application is crucial.
  • Further research holds potential for improved outcomes in MM patients through immunotherapy.